COMP <GO>
MYGN vs JNJ // REVENUE GROWTH (YOY)
Myriad Genetics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MYGN 2
— JNJ 8
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $6.67 (+0.60%) • MKT CAP: $638.0M
revenue-growth
-1.60%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MYGN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MYGN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.90% | 67.90% | +2.00 | MYGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.28% | 2.97% | -2.69 | JNJ | /fcf-yield <GO> |
| Operating Margin | -47.00% | 34.70% | -81.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -44.40% | 28.50% | -72.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -1.60% | 6.00% | -7.60 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.7 | 62.1 | +10.55 | MYGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $638.0M | $662.49B | -$661.85B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MYGN REV | JNJ REV | MYGN GROSS % | JNJ GROSS % | MYGN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $824.5M | $94.19B | 69.9% | 67.9% | $1.8M | $19.70B |
| FY 2024 | $837.6M | $88.82B | 69.9% | 69.1% | -$8.7M | $19.84B |
| FY 2023 | $753.2M | $85.16B | — | — | -$110.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MYGN // BETA —
JNJ // BETA 1.08